JP7134093B2 - ペグ化バイオアクティブペプチド及びその使用 - Google Patents

ペグ化バイオアクティブペプチド及びその使用 Download PDF

Info

Publication number
JP7134093B2
JP7134093B2 JP2018555634A JP2018555634A JP7134093B2 JP 7134093 B2 JP7134093 B2 JP 7134093B2 JP 2018555634 A JP2018555634 A JP 2018555634A JP 2018555634 A JP2018555634 A JP 2018555634A JP 7134093 B2 JP7134093 B2 JP 7134093B2
Authority
JP
Japan
Prior art keywords
peg
ghrh
seq
pharmaceutically acceptable
yadaiftac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018555634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516675A (ja
JP2019516675A5 (enExample
Inventor
クリシュナ・ジー・ペリ
Original Assignee
グリフォン・ファーマシューティカルズ・アンテルナシオナル・エスアー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリフォン・ファーマシューティカルズ・アンテルナシオナル・エスアー filed Critical グリフォン・ファーマシューティカルズ・アンテルナシオナル・エスアー
Publication of JP2019516675A publication Critical patent/JP2019516675A/ja
Publication of JP2019516675A5 publication Critical patent/JP2019516675A5/ja
Application granted granted Critical
Publication of JP7134093B2 publication Critical patent/JP7134093B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018555634A 2016-04-19 2017-04-18 ペグ化バイオアクティブペプチド及びその使用 Expired - Fee Related JP7134093B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324600P 2016-04-19 2016-04-19
US62/324,600 2016-04-19
PCT/CA2017/050475 WO2017181277A1 (en) 2016-04-19 2017-04-18 Pegylated bioactive peptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2019516675A JP2019516675A (ja) 2019-06-20
JP2019516675A5 JP2019516675A5 (enExample) 2021-11-11
JP7134093B2 true JP7134093B2 (ja) 2022-09-09

Family

ID=60039750

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018555634A Expired - Fee Related JP7134093B2 (ja) 2016-04-19 2017-04-18 ペグ化バイオアクティブペプチド及びその使用

Country Status (18)

Country Link
US (2) US10918730B2 (enExample)
EP (1) EP3445778B1 (enExample)
JP (1) JP7134093B2 (enExample)
KR (1) KR102520348B1 (enExample)
CN (1) CN109153712B (enExample)
AU (1) AU2017254754B2 (enExample)
BR (1) BR112018070929A2 (enExample)
CA (1) CA3021231A1 (enExample)
DK (1) DK3445778T3 (enExample)
ES (1) ES2824781T3 (enExample)
HU (1) HUE052802T2 (enExample)
IL (1) IL262356B2 (enExample)
MX (1) MX2018012716A (enExample)
PL (1) PL3445778T3 (enExample)
PT (1) PT3445778T (enExample)
RU (1) RU2748576C2 (enExample)
SG (1) SG11201808880PA (enExample)
WO (1) WO2017181277A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020205498A1 (en) 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh or analogues thereof for use in treatment of hepatic disease
CN116194344B (zh) 2020-10-09 2026-06-30 奥托立夫开发公司 安全气囊装置
CN114195881B (zh) * 2021-12-16 2022-09-16 浙江湃肽生物股份有限公司 一种制备醋酸舍莫瑞林的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659693A (en) 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4914189A (en) 1987-02-05 1990-04-03 The Adminstrators Of The Tulane Educational Fund Synthetic GHRH analogs
DE3726324A1 (de) 1987-08-07 1989-02-16 Hoechst Ag Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute
US5023322A (en) 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5137872A (en) 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
NZ238748A (en) 1990-06-29 1993-09-27 Hoffmann La Roche Growth hormone releasing factor (grf) analogues
US5847006A (en) 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
CA2084061A1 (en) 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
CA2158782C (en) 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
CA2218173A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
DK0828758T3 (da) 1995-05-26 2002-01-07 Theratechnologies Inc Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
KR20020047096A (ko) 1999-07-26 2002-06-21 크로커 사무엘 에스 초활성 돼지 성장 호르몬 분비 호르몬 유사체
US7256258B2 (en) 2000-10-05 2007-08-14 Ares Trading S.A. Regioselective liquid phase pegylation
EP1539959A2 (en) 2002-09-18 2005-06-15 Centre Hospitalier de l'Université de Montréal (CHUM) Ghrh analogues
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
AU2003229222B2 (en) 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
US8293708B2 (en) * 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
BRPI0915142A8 (pt) 2008-06-12 2018-01-02 Syntaxin Ltd Polipeptídeos, ácido nucleico e usos dos mesmos
US20110288011A1 (en) 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
BR112013027150A2 (pt) * 2011-04-21 2017-06-06 Theratechnologies Inc thera
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9079974B2 (en) 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
CN104946659A (zh) * 2015-03-27 2015-09-30 杭州北斗生物技术有限公司 重组人生长激素的制备方法及其peg化修饰物的制备方法
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Advanced Drug Delivery Reviews，2003年，55，p. 1279-1291

Also Published As

Publication number Publication date
EP3445778A4 (en) 2019-05-01
US20170296628A1 (en) 2017-10-19
PL3445778T3 (pl) 2021-02-22
RU2018140501A (ru) 2020-05-19
US10918730B2 (en) 2021-02-16
RU2748576C2 (ru) 2021-05-27
AU2017254754B2 (en) 2021-02-04
IL262356A (en) 2018-11-29
US20190209699A1 (en) 2019-07-11
KR102520348B1 (ko) 2023-04-10
US9988428B2 (en) 2018-06-05
EP3445778B1 (en) 2020-07-15
ES2824781T3 (es) 2021-05-13
PT3445778T (pt) 2020-10-15
DK3445778T3 (da) 2020-10-12
EP3445778A1 (en) 2019-02-27
BR112018070929A2 (pt) 2019-02-26
IL262356B2 (en) 2023-06-01
CA3021231A1 (en) 2017-10-26
JP2019516675A (ja) 2019-06-20
RU2018140501A3 (enExample) 2020-09-08
CN109153712B (zh) 2022-09-16
SG11201808880PA (en) 2018-11-29
WO2017181277A1 (en) 2017-10-26
KR20180135016A (ko) 2018-12-19
HUE052802T2 (hu) 2021-05-28
CN109153712A (zh) 2019-01-04
AU2017254754A1 (en) 2018-11-01
MX2018012716A (es) 2019-02-11

Similar Documents

Publication Publication Date Title
US12187773B2 (en) Modified GIP peptide analogues
CN111491658A (zh) 肠促胰岛素类似物及其用途
US20150252093A1 (en) Glucose-dependent insulinotropic polypeptide analogues
US20110136733A1 (en) Analogues of glucose-dependent insulinotropic polypeptide
US20110136724A1 (en) Analogues of glucose-dependent insulinotropic polypeptide
EP4613761A9 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20110166069A1 (en) Compositions and methods for stimulating gastrointestinal motility
JP2022551153A (ja) 活性ポリペプチド化合物
EP4658674A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
US10918730B2 (en) Pegylated bioactive peptides and uses thereof
CN104520314A (zh) 新的具有强效激动效果的gh-rh类似物
US8361964B2 (en) Growth hormone releasing factor (GRF) analogs and uses thereof
WO2024003359A1 (en) AMYLIN RECEPTOR (hAMY3R) AGONISTS WITH IMPROVED CHEMICAL STABILITY
CN117677628A (zh) Ghr结合未决肽及包含所述肽的组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181102

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210817

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220511

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220511

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220523

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220609

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220830

R150 Certificate of patent or registration of utility model

Ref document number: 7134093

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees